Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Haploidentical HSCT with rituximab and αβ T/B-cell depletion in pediatric patients unable to receive high-dose PT-CY
jRCT2032250318Phase 2Recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Feb 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab in conditions requiring allogeneic stem cell transplantation, Fanconi anemia (FA), DNA repair disorders and 4 more, sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Event-free survival at 100 days post-transplant. Started Feb 2026; status: recruiting.
02
Drugs
rituximab
03
Conditions
conditions requiring allogeneic stem cell transplantationFanconi anemia (FA)DNA repair disorderssevere combined immunodeficiency (SCID)hematopoietic malignancies
Beyond the preview
Go deeper on jRCT2032250318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2032250318.